253 related articles for article (PubMed ID: 36046748)
21. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
22. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience.
Chen VL; Yeh ML; Le AK; Jun M; Saeed WK; Yang JD; Huang CF; Lee HY; Tsai PC; Lee MH; Giama N; Kim NG; Nguyen PP; Dang H; Ali HA; Zhang N; Huang JF; Dai CY; Chuang WL; Roberts LR; Jun DW; Lim YS; Yu ML; Nguyen MH
Aliment Pharmacol Ther; 2018 Jul; 48(1):44-54. PubMed ID: 29797518
[TBL] [Abstract][Full Text] [Related]
23. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
[TBL] [Abstract][Full Text] [Related]
24. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
25. Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma.
Chen C; Liang T; Wu Q; Zhou Z; Zhang M; Feng D; Tao J; Si T; Cai M
Comput Math Methods Med; 2022; 2022():2940654. PubMed ID: 36578460
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B Before and After Hepatocellular Carcinoma.
Harputluoglu M; Carr BI
J Gastrointest Cancer; 2021 Dec; 52(4):1206-1210. PubMed ID: 34762265
[TBL] [Abstract][Full Text] [Related]
27. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.
Yu Y; Ai J; Zhang W
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):925-937. PubMed ID: 28661190
[TBL] [Abstract][Full Text] [Related]
28. Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology.
Sun J; Ma M; Zhong X; Li J; Yi J; Zhang R; Liu X; Peng L; Sun X; Feng W; Hu R; Huang Q; Lv M; Fan K; Zhou X
J Ethnopharmacol; 2024 Jun; 328():117985. PubMed ID: 38417600
[TBL] [Abstract][Full Text] [Related]
29. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology.
Liu Z; Ma H; Lai Z
BMC Complement Med Ther; 2021 Oct; 21(1):263. PubMed ID: 34663301
[TBL] [Abstract][Full Text] [Related]
30. Identification of Warning Transition Points from Hepatitis B to Hepatocellular Carcinoma Based on Mutation Accumulation for the Early Diagnosis and Potential Drug Treatment of HBV-HCC.
Xu F; Meng Q; Wu F; Wang Y; Yang W; Tong Y; Liu L; Chen X
Oxid Med Cell Longev; 2022; 2022():3472179. PubMed ID: 36105485
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Rizzo GEM; Cabibbo G; Craxì A
Viruses; 2022 May; 14(5):. PubMed ID: 35632728
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of long non-coding RNA expression profiles in hepatitis B virus-related hepatocellular carcinoma.
Gong X; Wei W; Chen L; Xia Z; Yu C
Oncotarget; 2016 Jul; 7(27):42422-42430. PubMed ID: 27285756
[TBL] [Abstract][Full Text] [Related]
34. Prevention of Hepatitis B Virus Infection and Liver Cancer.
Chang MH
Recent Results Cancer Res; 2021; 217():71-90. PubMed ID: 33200362
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.
Zhou HY; Luo Y; Chen WD; Gong GZ
J Gastroenterol Hepatol; 2015 Jun; 30(6):977-83. PubMed ID: 25689418
[TBL] [Abstract][Full Text] [Related]
36. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection.
Schemmer P; Burra P; Hu RH; Hüber CM; Loinaz C; Machida K; Vogel A; Samuel D
Liver Int; 2022 Feb; 42(2):288-298. PubMed ID: 34846790
[TBL] [Abstract][Full Text] [Related]
37. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study.
Wang R; Zang W; Hu B; Deng D; Ling X; Zhou H; Su M; Jiang J
Technol Cancer Res Treat; 2020; 19():1533033820980785. PubMed ID: 33308056
[TBL] [Abstract][Full Text] [Related]
38. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.
Lok AS; Everhart JE; Di Bisceglie AM; Kim HY; Hussain M; Morgan TR;
Hepatology; 2011 Aug; 54(2):434-42. PubMed ID: 21374690
[TBL] [Abstract][Full Text] [Related]
39. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.
Cho EJ; Kwack MS; Jang ES; You SJ; Lee JH; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():17-22. PubMed ID: 22156481
[TBL] [Abstract][Full Text] [Related]
40. [Study on molecular mechanism of Solanum nigrum in treatment of hepatocarcinoma based on network pharmacology and molecular docking].
Liu JH; Lyu DY; Zhou HM; Kuang WH; Chen ZX; Zhang SJ
Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):163-168. PubMed ID: 32237426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
